Introduction
The main features that characterize eyes with tilted disc syndrome are oval optic disc with oblique axis, inferonasal crescent, situs inversus of the retinal vessels, myopic astigmatism and visual field defects. [1] [2] [3] In addition, an inferior staphyloma is often associated with this syndrome and severe complications such as choroidal neovascularization (CNV) can occur when the border of the staphyloma lies across the macula. [4] [5] [6] [7] This CNV usually shows a classic pattern on fluorescein angiography (FA) resulting in significant visual loss.
Ranibizumab (Lucentis ® ; Genentech Inc, South San Francisco, California, USA) is a humanized antibody fragment designed to bind and inhibit all vascular endothelial growth factor-A (VEGF-A) isoforms. It was approved by the Food and Drug Administration (FDA) for the treatment of wet age-related macular degeneration in June 2006. It has shown a great efficacy in the management of all angiographic subtypes of lesions in different clinical trials. 8, 9 We present a case of CNV on the border of an inferior staphyloma associated with tilted disc syndrome successfully treated with intravitreal ranibizumab.
Case report
A 77-year-old woman complained about visual acuity (VA) loss in her left eye in the previous 3 weeks. She had an uncomplicated cataract surgery in both eyes 4 years 
Discussion
Severe visual loss has been reported on eyes with tilted disc syndrome when the upper-temporal border of an inferior staphyloma lies across the macula. It has been hypothesized that the sharp curve on the border of the staphyloma causes mechanical or hemodynamic changes and promotes the development of macular complications. 2 Several published papers have described CNV in these cases. [5] [6] [7] Recently, Nakanishi et al 4 reviewed 32 eyes of 20 patients with tilted disc syndrome and inferior staphyloma lying across the macula. They found macular complications in 78% of the patients consisting of polypoidal choroidal vasculopathy (PCV) (22%), classic CNV (3%), focal serous retinal detachment without PCV or CNV (41%) and atrophy of the RPE alone (13%). The VA of eyes with PCV or CNV was significantly worse than in the other cases. However, they did not report the long-term evolution and visual outcome and the proposed treatment.
We decided to treat our patient with intravitreal ranibizumab with the recommended standard protocol of treatment. 10 Ranibizumab is indicated for choroidal neovascular lesions with active disease with three initial consecutive monthly injections (loading dose) and thereafter monthly monitoring based on VA, fundus examination and OCT findings. This flexible strategy of treatment is effective and more feasible than continued monthly injections used in pivotal clinical trials. 8, 9 In our case, VA improved with resolution of angiographic leakage and OCT scanning edema. After the loading dose, our patient did not require any additional injection during the 9-month follow-up period. Nevertheless, it is likely that further treatment will be required with longer follow-up. We did not have any ocular or systemic side effect related to the drug or the route of administration.
The VA improved by one line, from 20/40 to 20/32. In comparison, a much more substantial anatomical benefit was observed, with resolution of the angiographic leakage and the intraretinal and subretinal fluid detected on OCT scans. However, it is known that visual gaining is often limited in predominantly classic lesions growing between the photoreceptors and the RPE.
Photodynamic therapy with verteporfin could have been used as an alternative treatment in this patient. However, potential RPE damage could have limited visual recovery. 11 Bevacizumab could have been used as an alternative treatment. However, it is not an approved drug for intraocular use in Spain. RPE rips have been reported with ranibizumab and bevacizumab as well. To our knowledge, no data support reduced risk of RPE rips with either ranibizumab or bevacizumab.
In summary, ranibizumab therapy can be used as an efficacious and safe treatment in the management of CNV associated with tilted disc syndrome. Nevertheless, this is only supported by a single case report. It would be desirable to accumulate more data to demonstrate potential safety and efficacy of ranibizumab in this condition.
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